Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | ||
Market Cap | 43.15 Cr. | |
Enterprise Value(EV) | 105.87 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 0.75 | Trailing Twelve Months Ending 2022-09 |
Price-Earning Ratio (PE) | 38.45 | Trailing Twelve Months Ending 2022-09 |
Industry PE | 32.22 | Trailing Twelve Months Ending 2022-09 |
Book Value / Share | 33.04 | Trailing Twelve Months Ending 2022-09 |
Price to Book Value | 0.88 | Calculated using Price: 28.95 |
Dividend Yield | 0.00 | Period Ending 2022-03 |
No. of Shares Subscribed | 1.49 Cr. | 14,903,520 Shares |
FaceValue | 10 | |
Company Profile | ||
Vivo Bio Tech was incorporated on February 12, 1987 as Golden Growth Fund, Hyderabad-based Vivo Bio Tech (VBTL) is a contract research company engaged in biotechnology and pharma drug discovery activities. The company was converted into a public limited company from Jun. 19, 1992. VBTL provides services ranging from insilico design, wet lab contract research, preclinical research and clinical studies spanning the entire drug discovery value chain. |
1 Day |
|
+0.87% |
1 Week |
|
-1.03% |
1 Month |
|
-3.34% |
3 Month |
|
-21.54% |
6 Month |
|
-9.95% |
1 Year |
|
-56.89% |
2 Year |
|
-46.49% |
5 Year |
|
-38.79% |
10 Year |
|
+104.30% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 3.52 | 5.25 | 9.48 | 22.17 | 21.01 | 10.21 | 14.85 | 15.36 | 5.06 | |
Return on Capital Employed (%) | 7.95 | 4.72 | 5.96 | 12.39 | 15.18 | 9.58 | 13.85 | 18.81 | 9.32 | |
Return on Assets (%) | 0.75 | 1.14 | 2.09 | 5.17 | 5.64 | 3.92 | 7.58 | 8.02 | 2.18 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 9 | 9 | 10 | 13 | 19 | 27 | 33 | 43 | 47 | 50 | |
Non Curr. Liab. | 5 | 4 | 15 | 22 | 15 | 9 | 9 | 15 | 52 | 50 | |
Curr. Liab. | 26 | 28 | 20 | 17 | 25 | 19 | 21 | 22 | 23 | 23 | |
Minority Int. | |||||||||||
Equity & Liab. | 40 | 41 | 46 | 51 | 60 | 55 | 62 | 80 | 122 | 122 | |
Non Curr. Assets | 21 | 20 | 24 | 32 | 32 | 30 | 35 | 52 | 96 | 94 | |
Curr. Assets | 19 | 22 | 22 | 20 | 28 | 25 | 27 | 27 | 26 | 28 | |
Misc. Exp. not W/O | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
Total Assets | 40 | 41 | 46 | 51 | 60 | 55 | 62 | 80 | 122 | 122 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09 Rs. Cr. TTM |
Net Sales | 16 | 18 | 29 | 34 | 47 | 56 | 55 | 52 | 51 | 52 | |
Other Income | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Total Income | 17 | 19 | 29 | 35 | 47 | 56 | 55 | 52 | 51 | 52 | |
Total Expenditure | -14 | -15 | -25 | -27 | -36 | -46 | -43 | -34 | -35 | -35 | |
PBIDT | 3 | 4 | 5 | 8 | 11 | 10 | 13 | 18 | 16 | 17 | |
Interest | 0 | -1 | 0 | -1 | -2 | -3 | -3 | -4 | -4 | -6 | |
Depreciation | -2 | -3 | -3 | -4 | -5 | -5 | -5 | -6 | -7 | -9 | |
Taxation | 0 | 0 | 0 | 0 | -1 | 0 | 0 | -3 | -2 | -1 | |
Exceptional Items | |||||||||||
PAT | 0 | 0 | 1 | 3 | 3 | 2 | 4 | 6 | 2 | 1 | |
Minority Interest | |||||||||||
Share Associate | |||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 0 | 0 | 1 | 3 | 3 | 2 | 4 | 6 | 2 | 1 | |
Adjusted EPS | 0 | 0 | 1 | 3 | 3 | 2 | 3 | 4 | 2 | 1 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 2 | 3 | 2 | 9 | -6 | 11 | -1 | 9 | 14 | 14 | |
Cash Fr. Inv. | 25 | -1 | -2 | -7 | -12 | -5 | -4 | -10 | -23 | -51 | |
Cash Fr. Finan. | -19 | 0 | -1 | 0 | 7 | -3 | 1 | 2 | 9 | 38 | |
Net Change | 8 | 1 | -1 | 1 | -11 | 3 | -4 | 0 | 0 | 1 | |
Cash & Cash Eqvt | 10 | 11 | 11 | 12 | 1 | 4 | 1 | 1 | 1 | 2 |
Mon, 30 Jan 2023
Board Meeting Intimation for Un-Audited Standalone & Consolidated Financial Results Of The Company For The Quarter And Nine Months Ended December 31 2022. VIVO BIO TECH LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2023 inter alia to consider and approve the Un-Audited Standalone & Consolidated Financial Results of the Company for the Quarter and Nine Months ended December 31 2022. |
Tue, 10 Jan 2023
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Vivo Bio Tech Limited has submitted with the exchange the certificate received from M/s. Aarthi Consultants Private Limited (Registrar and Share Transfer Agent) for the period from October 01 2022 to December 31 2022 under SEBI (Depositories and Participants) Regulations 2018. |
Wed, 04 Jan 2023
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS Vivo Bio Tech Limited has informed the exchange that the Company has today allotted 27 000 Equity Shares under Vivo Bio Employees Stock Option Scheme 2016 to the eligible employees of the Company pursuant to the exercise of options granted.Consequently the issued and Subscribed Share Capital of the Company stands increased to Rs. 14 90 35 200 divided into 1 49 03 520 Equity Shares of Rs.10/- each. |
Fri, 03 Feb 2023 |
|
|
|
|
|